大连华立金港药业

Dalian Huali Jingang Pharmaceutical Co., Ltd., founded in 1971 and based in Dalian, China, is a commercial-stage pharmaceutical company specializing in the development, manufacturing, and commercialization of oncology therapeutics and traditional Chinese medicine. The company is recognized as a pioneer in the industrialization of natural anti-tumor drugs and targeted lipid emulsion formulations in China. Its flagship products include Elemene Injection and Elemene Oral Emulsion, which are proprietary, plant-derived anti-cancer drugs widely used to treat various malignancies such as lung, liver, and brain cancers. Additionally, the company produces Xuekang Oral Liquid for thrombocytopenia and Jingling Oral Liquid for pediatric attention deficit hyperactivity disorder. In 2025, the company was acquired by CSPC Pharmaceutical Group (石药集团) through Changde Jingze.